Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

NCT00854087 is registered in ClinicalTrials.gov with Tarek Hassanein as lead sponsor.

NCT NCT00854087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00854087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis
Lead sponsor
Tarek Hassanein
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
August 31, 2013
Enrollment
118 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c infection